Velleca Mark A.
- SEC CIK
- 0001706847
No open-market purchases or sales filed in the past year.
Current role at each company
- BDTX Black Diamond Therapeutics, Inc.PRESIDENT & CEOas of Jan 23, 2026
- GTHX G1 Therapeutics, Inc.Directoras of Aug 10, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Velleca Mark A. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
GTHX G1 Therapeutics, Inc.
Director5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2023 (view filing)4:11 PM ET | Aug 8 | 2 days | Velleca Mark A.Director | SSale | −60.0K | $2.00 | −$120.0K | −34.1%116.0K after | 2 lots10b5-1 |
| Oct 20, 2022 (view filing)4:05 PM ET | Oct 18 | 2 days | Velleca Mark A.Director | SSale | −15.0K | $11.70 | −$175.5K | −11.5%116.0K after | |
| Sep 22, 2022 (view filing)4:40 PM ET | Sep 20 | 2 days | Velleca Mark A.Director | SSale | −20.0K | $13.50 | −$270.0K | −14.7%116.0K after | |
| Aug 18, 2022 (view filing)4:06 PM ET | Aug 16 | 2 days | Velleca Mark A.Director | SSale | −80.0K | $12.64 | −$1.01M | −40.8%116.0K after | |
| Jul 15, 2021 (view filing)4:01 PM ET | Jul 13-15 | 2 days | Velleca Mark A.Director | SSale | −30.0K | $19.01 | −$570.3K | −33.0%61.0K after | 3 lots |